Leerink Partnrs Has Pessimistic View of Repligen Q2 Earnings

Repligen Co. (NASDAQ:RGEN) – Stock analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for shares of Repligen in a research report issued to clients and investors on Tuesday, April 29th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will post earnings per share of $0.39 for the quarter, down from their previous estimate of $0.42. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q3 2025 earnings at $0.39 EPS, FY2025 earnings at $1.67 EPS and FY2026 earnings at $2.14 EPS.

Several other brokerages have also weighed in on RGEN. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Monday, April 28th. Wolfe Research upgraded shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target on the stock in a research note on Tuesday. Finally, Canaccord Genuity Group reduced their price target on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research report on Wednesday, April 16th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $173.25.

Repligen Stock Performance

NASDAQ:RGEN opened at $141.51 on Friday. The firm has a market capitalization of $7.95 billion, a PE ratio of -277.47, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business’s fifty day moving average price is $137.82 and its 200 day moving average price is $145.81. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The firm’s quarterly revenue was up 10.4% on a year-over-year basis.

Insider Buying and Selling

In related news, Director Margaret Pax acquired 250 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its stake in Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after buying an additional 743,815 shares during the period. Vanguard Group Inc. increased its stake in shares of Repligen by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock worth $734,251,000 after acquiring an additional 56,723 shares during the period. Champlain Investment Partners LLC raised its holdings in Repligen by 8.6% during the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock worth $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. lifted its position in Repligen by 23.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock valued at $145,508,000 after purchasing an additional 191,439 shares during the period. Finally, Conestoga Capital Advisors LLC boosted its holdings in Repligen by 3.4% in the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company’s stock valued at $124,727,000 after purchasing an additional 32,665 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.